
Xalaprost0.005%
Beximco Pharmaceuticals Ltd.
Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with: Open-angle glaucoma — an FDA-approved and more.
Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with:
In specialist practice, Latanoprost is also used off-label in the management of certain forms of pediatric and secondary glaucomas under close ophthalmologist supervision, although this is not an FDA-approved use and safety/efficacy have not been formally established in children.
The recommended dose of Latanoprost is one drop in the affected eye(s) once daily, in the evening. The dose should not exceed once daily, as more frequent administration has been shown to paradoxically reduce the IOP-lowering effect of Latanoprost.
A specific pediatric dosing regimen for Latanoprost has not been established; safety and efficacy in children have not been formally demonstrated (see Use in Special Populations).
No dose adjustment of Latanoprost is required for renal or hepatic impairment based on available data, as systemic exposure after ocular administration is minimal.
The most common side effects of Latanoprost affect the eyes and are generally mild to moderate.
Latanoprost is contraindicated in patients with known hypersensitivity to Latanoprost, benzalkonium chloride, or any other ingredient in the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.